Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines

Tao Xie, Liqiong Tong, Michael W. McLane, George Hatzidimitriou, Jie Yuan, Una D McCann, George Ricaurte

Research output: Contribution to journalArticle

Abstract

We studied in vivo expression of the serotonin transporter (SERT) protein after 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine (PCA), or fenfluramine (FEN) treatments, and compared the effects of substituted amphetamines to those of 5,7-dihydroxytryptamine (5,7-DHT), an established serotonin (5-HT) neurotoxin. All drug treatments produced lasting reductions in 5-HT, 5-HIAA, and [3H]paroxetine binding, but no significant change in the density of a 70 kDa band initially thought to correspond to the SERT protein. Additional Western blot studies, however, showed that the 70 kDa band did not correspond to the SERT protein, and that a diffuse band at 63-68 kDa, one that had the anticipated regional brain distribution of SERT protein (midbrain>striatum>neocortex>cerebellum), was reduced after 5,7-DHT and was absent in SERT-null animals, was decreased after MDMA, PCA, or FEN treatments. In situ immunocytochemical (ICC) studies with the same two SERT antisera used in Western blot studies showed loss of SERT-immunoreactive (IR) axons after 5,7-DHT and MDMA treatments. In the same animals, tryptophan hydroxylase (TPH)-IR axon density was comparably reduced, indicating that serotonergic deficits after substituted amphetamines differ from those in SERT-null animals, which have normal TPH levels but, in the absence of SERT, develop apparent neuroadaptive changes in 5-HT metabolism. Together, these results suggest that lasting serotonergic deficits after MDMA and related drugs are unlikely to represent neuroadaptive metabolic responses to changes in SERT trafficking, and favor the view that substituted amphetamines have the potential to produce a distal axotomy of brain 5-HT neurons.

Original languageEnglish (US)
Pages (from-to)2639-2651
Number of pages13
JournalNeuropsychopharmacology
Volume31
Issue number12
DOIs
StatePublished - Dec 4 2006

Fingerprint

Amphetamines
N-Methyl-3,4-methylenedioxyamphetamine
Serotonin Plasma Membrane Transport Proteins
5,7-Dihydroxytryptamine
Serotonin
Proteins
p-Chloroamphetamine
Tryptophan Hydroxylase
Fenfluramine
Axons
Western Blotting
Axotomy
Paroxetine
Hydroxyindoleacetic Acid
Neocortex
Neurotoxins
Brain
Mesencephalon
Pharmaceutical Preparations
Cerebellum

Keywords

  • Amphetamine
  • Fenfluramine
  • MDMA
  • Neurotoxicity
  • p-chloroamphetamine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. / Xie, Tao; Tong, Liqiong; McLane, Michael W.; Hatzidimitriou, George; Yuan, Jie; McCann, Una D; Ricaurte, George.

In: Neuropsychopharmacology, Vol. 31, No. 12, 04.12.2006, p. 2639-2651.

Research output: Contribution to journalArticle

Xie, Tao ; Tong, Liqiong ; McLane, Michael W. ; Hatzidimitriou, George ; Yuan, Jie ; McCann, Una D ; Ricaurte, George. / Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. In: Neuropsychopharmacology. 2006 ; Vol. 31, No. 12. pp. 2639-2651.
@article{e5b3e4c3ccce4cdb8e320a54187842aa,
title = "Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines",
abstract = "We studied in vivo expression of the serotonin transporter (SERT) protein after 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine (PCA), or fenfluramine (FEN) treatments, and compared the effects of substituted amphetamines to those of 5,7-dihydroxytryptamine (5,7-DHT), an established serotonin (5-HT) neurotoxin. All drug treatments produced lasting reductions in 5-HT, 5-HIAA, and [3H]paroxetine binding, but no significant change in the density of a 70 kDa band initially thought to correspond to the SERT protein. Additional Western blot studies, however, showed that the 70 kDa band did not correspond to the SERT protein, and that a diffuse band at 63-68 kDa, one that had the anticipated regional brain distribution of SERT protein (midbrain>striatum>neocortex>cerebellum), was reduced after 5,7-DHT and was absent in SERT-null animals, was decreased after MDMA, PCA, or FEN treatments. In situ immunocytochemical (ICC) studies with the same two SERT antisera used in Western blot studies showed loss of SERT-immunoreactive (IR) axons after 5,7-DHT and MDMA treatments. In the same animals, tryptophan hydroxylase (TPH)-IR axon density was comparably reduced, indicating that serotonergic deficits after substituted amphetamines differ from those in SERT-null animals, which have normal TPH levels but, in the absence of SERT, develop apparent neuroadaptive changes in 5-HT metabolism. Together, these results suggest that lasting serotonergic deficits after MDMA and related drugs are unlikely to represent neuroadaptive metabolic responses to changes in SERT trafficking, and favor the view that substituted amphetamines have the potential to produce a distal axotomy of brain 5-HT neurons.",
keywords = "Amphetamine, Fenfluramine, MDMA, Neurotoxicity, p-chloroamphetamine",
author = "Tao Xie and Liqiong Tong and McLane, {Michael W.} and George Hatzidimitriou and Jie Yuan and McCann, {Una D} and George Ricaurte",
year = "2006",
month = "12",
day = "4",
doi = "10.1038/sj.npp.1301031",
language = "English (US)",
volume = "31",
pages = "2639--2651",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines

AU - Xie, Tao

AU - Tong, Liqiong

AU - McLane, Michael W.

AU - Hatzidimitriou, George

AU - Yuan, Jie

AU - McCann, Una D

AU - Ricaurte, George

PY - 2006/12/4

Y1 - 2006/12/4

N2 - We studied in vivo expression of the serotonin transporter (SERT) protein after 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine (PCA), or fenfluramine (FEN) treatments, and compared the effects of substituted amphetamines to those of 5,7-dihydroxytryptamine (5,7-DHT), an established serotonin (5-HT) neurotoxin. All drug treatments produced lasting reductions in 5-HT, 5-HIAA, and [3H]paroxetine binding, but no significant change in the density of a 70 kDa band initially thought to correspond to the SERT protein. Additional Western blot studies, however, showed that the 70 kDa band did not correspond to the SERT protein, and that a diffuse band at 63-68 kDa, one that had the anticipated regional brain distribution of SERT protein (midbrain>striatum>neocortex>cerebellum), was reduced after 5,7-DHT and was absent in SERT-null animals, was decreased after MDMA, PCA, or FEN treatments. In situ immunocytochemical (ICC) studies with the same two SERT antisera used in Western blot studies showed loss of SERT-immunoreactive (IR) axons after 5,7-DHT and MDMA treatments. In the same animals, tryptophan hydroxylase (TPH)-IR axon density was comparably reduced, indicating that serotonergic deficits after substituted amphetamines differ from those in SERT-null animals, which have normal TPH levels but, in the absence of SERT, develop apparent neuroadaptive changes in 5-HT metabolism. Together, these results suggest that lasting serotonergic deficits after MDMA and related drugs are unlikely to represent neuroadaptive metabolic responses to changes in SERT trafficking, and favor the view that substituted amphetamines have the potential to produce a distal axotomy of brain 5-HT neurons.

AB - We studied in vivo expression of the serotonin transporter (SERT) protein after 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine (PCA), or fenfluramine (FEN) treatments, and compared the effects of substituted amphetamines to those of 5,7-dihydroxytryptamine (5,7-DHT), an established serotonin (5-HT) neurotoxin. All drug treatments produced lasting reductions in 5-HT, 5-HIAA, and [3H]paroxetine binding, but no significant change in the density of a 70 kDa band initially thought to correspond to the SERT protein. Additional Western blot studies, however, showed that the 70 kDa band did not correspond to the SERT protein, and that a diffuse band at 63-68 kDa, one that had the anticipated regional brain distribution of SERT protein (midbrain>striatum>neocortex>cerebellum), was reduced after 5,7-DHT and was absent in SERT-null animals, was decreased after MDMA, PCA, or FEN treatments. In situ immunocytochemical (ICC) studies with the same two SERT antisera used in Western blot studies showed loss of SERT-immunoreactive (IR) axons after 5,7-DHT and MDMA treatments. In the same animals, tryptophan hydroxylase (TPH)-IR axon density was comparably reduced, indicating that serotonergic deficits after substituted amphetamines differ from those in SERT-null animals, which have normal TPH levels but, in the absence of SERT, develop apparent neuroadaptive changes in 5-HT metabolism. Together, these results suggest that lasting serotonergic deficits after MDMA and related drugs are unlikely to represent neuroadaptive metabolic responses to changes in SERT trafficking, and favor the view that substituted amphetamines have the potential to produce a distal axotomy of brain 5-HT neurons.

KW - Amphetamine

KW - Fenfluramine

KW - MDMA

KW - Neurotoxicity

KW - p-chloroamphetamine

UR - http://www.scopus.com/inward/record.url?scp=33746088858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746088858&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1301031

DO - 10.1038/sj.npp.1301031

M3 - Article

C2 - 16452989

AN - SCOPUS:33746088858

VL - 31

SP - 2639

EP - 2651

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 12

ER -